NCT06174857招募中不适用
Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2021年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥18 years.
- •Provision of fully informed consent prior to any study specific procedures.
- •Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
- •According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: 3 years
From registration onto that step until death, or censored at the date of last contact.
progression-free survival
时间窗: 3 years
From registration onto that step until death, or censored at the date of last contact.
次要结局
未报告次要终点
研究者
Yongchang Zhang
Professor, Deputy Director of Thoracic Oncology Department
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A multi-institutional retrospective study of osimertinib for elderly patients with previously untreated advanced non-small cell lung cancer harboring EGFR mutations (HOT2002)non-small cell lung cancerJPRN-UMIN000044101Hokkaido Lung Cancer Clinical Study Group(HOT)132
进行中（未招募）
不适用
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCCarcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsNCT06376084AstraZeneca532
招募中
不适用
A prospective observational study of osimertinib as predictive marker against patients with EGFR mutation positive NSCLC.ung CancerJPRN-UMIN000040432Gunma University50
未知
不适用
A prospective observational study of osimertinib as predictive marker against patients with EGFR T790M-positive NSCLC.ung CancerJPRN-UMIN000027233Gunma University45
撤回
不适用
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.Carcinoma, Non-Small-Cell LungNCT06075615Pfizer100